European journal of hospital pharmacy : science and practice最新文献

{"title":"Medication safety strategies in European adult, paediatric, and neonatal intensive care units: a cross-sectional survey.","authors":"Shahd Abdelaziz, Angela Amigoni, Minna Kurttila, Raisa Laaksonen, Virginia Silvari, Bryony Dean Franklin","doi":"10.1136/ejhpharm-2023-004018","DOIUrl":"10.1136/ejhpharm-2023-004018","url":null,"abstract":"<p><strong>Objectives: </strong>Patients in intensive care units (ICUs) are potentially more vulnerable to medication errors than patients admitted to general wards. However, little is known about medication safety strategies used in European ICUs. Our objectives were to explore the strategies being used and being planned within European ICUs, to identify areas of variation, and to inform recommendations to improve medication safety in this patient group.</p><p><strong>Methods: </strong>We distributed an online survey, in seven European languages, via professional networks and social media. The survey explored a range of medication safety strategies and whether they were in use (and if so, whether fully or partially implemented) or being planned. Demographic information about respondents and their ICUs was also captured. A descriptive analysis was conducted, which included exploring geographical variation.</p><p><strong>Results: </strong>We obtained 587 valid responses from 32 different countries, with 317 (54%) completed by pharmacy staff. Medication safety practices most commonly implemented were patients' allergies being visible for all staff involved in their care (fully implemented in 382 (65%) of respondents' ICUs), standardised emergency medication stored in a fixed place (337, 57%), and use of standardised medication concentrations for commonly used intravenous infusions (330, 56%). Electronic prescribing systems were fully implemented in 310 (53%). A pharmacist was reported to be fully implemented in 181 (31%) of ICUs, of which there was 126 (70%) where there was a pharmacist review of all ordered medication five days per week. Critical care pharmacists were most common in Northern European ICUs (fully implemented to ICUs in 102, 50%) and electronic prescribing in Western Europe (108, 65%).</p><p><strong>Conclusions: </strong>There is considerable variation in medication safety strategies used within European ICUs, both between and within geographical areas. Our findings may be helpful to ICU staff in identifying strategies that should be considered for implementation.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"113-120"},"PeriodicalIF":1.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141247477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious diseases and antimicrobial resistance.","authors":"Darija Kuruc Poje, Nenad Miljković, Piera Polidori, Stephanie Kohl","doi":"10.1136/ejhpharm-2023-003920","DOIUrl":"10.1136/ejhpharm-2023-003920","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"186-189"},"PeriodicalIF":1.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10492432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential risk of non-arteritic anterior ischaemic optic neuropathy in semaglutide users: pharmacovigilance insights.","authors":"Eleonora Castellana","doi":"10.1136/ejhpharm-2024-004333","DOIUrl":"10.1136/ejhpharm-2024-004333","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"194"},"PeriodicalIF":1.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142145468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Older people, medication usage and long-term care pharmacists: a retrospective cohort study.","authors":"João Rafael Gonçalves, Betsy L Sleath, Mariana Cerdeira, Afonso Miguel Cavaco","doi":"10.1136/ejhpharm-2023-003908","DOIUrl":"10.1136/ejhpharm-2023-003908","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the impact of the presence of a pharmacist on medication usage in long-term care facilities.</p><p><strong>Methods: </strong>The study followed a retrospective cohort design, with a sample of patients aged ≥65 years admitted to three long-term care facilities over 30 months. Data on age, gender, type of stay, the presence or absence of a pharmacist and pharmacotherapeutic profile at admission and discharge were obtained for study patients. Variations in the number of medicines, anticholinergic burden and potentially inappropriate medications at admission and discharge were assessed as outcome variables. Anticholinergic burden and potentially inappropriate medications were assessed using the Anticholinergic Cognitive Burden scale and the EU(7)-PIM List, respectively. One-sample t-tests were used to compare the mean values of the outcome variables. A four-way ANOVA was used to test the association between background and outcome variables. Partial eta squared (η²) was used to measure the effect size.</p><p><strong>Results: </strong>A total of 1366 patients were studied. All outcome variables showed a statistically significant increase at discharge compared with admission. The presence of a pharmacist was statistically significant in improving the number of medicines (p<0.001) and the anticholinergic burden score (p<0.001), while no statistically significant value was reached on potentially inappropriate medications (p=0.642). Small effect size values were obtained for the impact of the pharmacist on the number of medicines and anticholinergic burden scores (η²=0.021 and η²=0.011, respectively).</p><p><strong>Conclusion: </strong>These findings suggest that the presence of a long-term care pharmacist can positively impact the use of medication associated with poor health outcomes. An integrated interprofessional approach is needed to address potentially inappropriate medications, anticholinergic burden and polypharmacy in long-term care settings, particularly at the time of discharge.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"137-142"},"PeriodicalIF":1.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41120305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of hospital pharmacy services at transition of care points: a scoping review.","authors":"Jasmin Theresa Stoll, Anita Elaine Weidmann","doi":"10.1136/ejhpharm-2023-003836","DOIUrl":"10.1136/ejhpharm-2023-003836","url":null,"abstract":"<p><strong>Background: </strong>Several hospital pharmacy services exist, which take place at different interfaces of patient care. Although they are an important tool for improving medication safety, they are not yet sufficiently implemented in hospitals around the world.</p><p><strong>Objective: </strong>This scoping review aims to summarise different hospital pharmacy services at transition of care (TOC) points in order to identify development trends and practice patterns in high-income countries over the past decade.</p><p><strong>Methods: </strong>A literature search of four databases (PubMed, PubPharm, Cochrane Library (Ovid) and ScienceDirect) since 2011 was conducted. A detailed search strategy was developed and refined with the help of a research librarian. Title, abstract and full-text selection was carried out by two researchers independently. The study was reported in accordance with the PRISMA-ScR items to ensure quality standard reporting. Only studies originating from developed countries and published in the English language were included. The data obtained were extracted and summarised using a data extraction form developed to meet the research aims of the study.</p><p><strong>Results: </strong>Of the 5456 search results, 65 studies met the inclusion criteria. These originated from Europe (n=29), North America/Canada (n=28), Australia (n=7) and Asia (n=1). Individual TOC services such as medication reconciliation and medication review on admission and at discharge were the main focus of published literature practice patterns between 2011 and 2016, after which a more holistic TOC service started to emerge that follows patients across all TOC points during their hospital stay. Facilitators and barriers were consistently dependent on resources and infrastructure. Clinical and economic outcomes show a mixed picture.</p><p><strong>Conclusion: </strong>During the past decade pharmaceutical services have developed more holistic TOC services. Large-scale high-quality studies are needed to reliably determine clinical and economic benefit.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":"106-112"},"PeriodicalIF":1.6,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139989745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic drug monitoring of linezolid in a case of pulmonary nocardiosis: a case report.","authors":"María Calvo, Mónica Beunza Sola, Bianka Tirapu, Maite Sarobe Carricas, Estela Moreno","doi":"10.1136/ejhpharm-2024-004462","DOIUrl":"https://doi.org/10.1136/ejhpharm-2024-004462","url":null,"abstract":"<p><p>This clinical case discusses a man between 60 and 70 years old with lung adenocarcinoma who developed a <i>Nocardia cyriacigeorgica</i> infection. Because it is an intracellular bacterium, we need to start antibiotic treatment and maintain for a year. For initial therapy, sulfamethoxazole/trimethoprim (SMX/TMP) is the preferred antibiotic, but it can cause side effects, such as liver damage. Linezolid is another valid alternative.Pharmacokinetic monitoring of linezolid was essential in managing the patient because the drug can cause significant side effects like myelosuppression. The pharmacist tracked serum levels over 7 months, allowing for dose adjustments that minimised toxicity and ensured effective treatment. Elevated linezolid levels were linked to thrombocytopenia, prompting timely dosage modifications that improved the patient's haemoglobin and platelet counts.This case highlights the critical role of pharmacokinetic monitoring in optimising linezolid therapy. The pharmacist's involvement enhanced treatment efficacy, but also safeguarded the patient from serious adverse effects, demonstrating the importance of collaborative healthcare.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143467442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Algorithm-managed dosing and pharmacist-managed dosing of erythropoietin stimulating agents in renal anaemia: a systematic review.","authors":"Francisca Johanna van den Oever, Marijke J E Dekker, Erwin C Vasbinder, Teun van Gelder, Patricia M L A Van den Bemt","doi":"10.1136/ejhpharm-2024-004366","DOIUrl":"https://doi.org/10.1136/ejhpharm-2024-004366","url":null,"abstract":"<p><strong>Objectives: </strong>The goal of this systematic review was to identify and summarise algorithm-managed and pharmacist-managed dosing of erythropoietin stimulating agents (ESA) in patients with renal anaemia and to determine the effects on available outcome parameters.</p><p><strong>Methods: </strong>We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines for systematic reviews. Studies investigating algorithm-managed and pharmacist-managed dosing of ESA in adult patients with renal anaemia were evaluated for inclusion. No restrictions were set on outcome parameters. Observational and interventional studies available as full-text articles with a control group and follow-up ≥6 months were eligible for inclusion. Relevant databases were searched from their inception through August 2024. Two independent reviewers evaluated all studies. The risk of bias was assessed by the ROBINS-I and RoB1 tools. The protocol of this study was registered in PROSPERO (CRD42021243678).</p><p><strong>Results: </strong>After screening 140 articles, 17 articles and 4313 patients could be included. Available evidence was of low to moderate quality with a high risk of bias. Data were summarised and tabulated. Meta-analysis was not possible due to the substantial heterogeneity in participants, study design, interventions, comparisons, and outcome parameters. However, standardised metrics could be identified and calculated for haemoglobin and ESA dose. The percentage in target range for haemoglobin varied between 3.5% lower (95% CI -18.67% to +11.67%) to 32.0% higher (95% CI 14.07% to 49.93%) in the pharmacist-managed group versus the control group (n=1401). The range in reduction in ESA dose was 5.45% (95% CI -7.97% to +18.87%) to 49.97% (95% CI 20.32% to 79.61%) in the pharmacist-managed group versus the control group (n=2115).</p><p><strong>Conclusion: </strong>Low-quality data with high risk of bias suggest that pharmacist-managed renal anaemia may improve the percentage of haemoglobin within target range and reduce the ESA dose. However, meta-analysis was impossible due to substantial heterogeneity. Therefore, no definite conclusions could be drawn on the effectiveness of pharmacist-managed dosing of ESA in renal anaemia.</p><p><strong>Prospero registration number: </strong>CRD42021243678.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143457242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing global hospital pharmacy: the enduring impact and call to action of the FIP Basel Statements.","authors":"Henri Manasse, Esteban Zavaleta","doi":"10.1136/ejhpharm-2025-004490","DOIUrl":"https://doi.org/10.1136/ejhpharm-2025-004490","url":null,"abstract":"","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution rate of prescribing errors after advice from a specialised hospital pharmacist or a substitute hospital pharmacist: a retrospective cross-sectional study.","authors":"Sarah Wilkes, Laura Kalfsvel, Floor van Rosse, Jorie Versmissen, Hugo van der Kuy, Rianne Zaal","doi":"10.1136/ejhpharm-2024-004392","DOIUrl":"https://doi.org/10.1136/ejhpharm-2024-004392","url":null,"abstract":"<p><strong>Objectives: </strong>Specialised hospital pharmacists, integrated in medical teams on the ward, can improve medication safety. When a specialised hospital pharmacist is temporarily not available, the pharmaceutical care will be conducted by a substitute hospital pharmacist with less specific knowledge about that patient population. Our objective was to compare the resolution rate of prescribing errors between specialised hospital pharmacists and their substitutes. Furthermore, we investigated whether other characteristics of the pharmacists, the prescriber, patient, drug or intervention itself were associated with the resolution rate.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted to assess the resolution of prescribing errors, based on the analysis of electronic prescriptions. A prescribing error was defined as an alert that required intervention of the pharmacist to prevent harm or to optimise therapy. To identify prescribing errors, a medical doctor and hospital pharmacist analysed all alerts that were retained to be checked by a pharmacist. Resolution of a prescribing error was defined as resolution of the error within 24 hours after detection.</p><p><strong>Results: </strong>In total, 145 574 medication prescriptions were analysed and 448 prescribing errors were detected. Of these prescribing errors, 94.0% were resolved within 24 hours. No differences were found between the resolution rate of prescribing errors after advice from a specialised hospital pharmacists and their substitutes (94.4% vs 91.9%, p=0145 (χ² test)). Administrative prescribing errors, prescribing errors for patients aged >80 years and prescribing errors handled during weekends showed a relatively low-resolution rate. No other characteristics of the pharmacist, prescriber, patient, the drug involved or the intervention itself were associated with the resolution of the prescribing error.</p><p><strong>Conclusions: </strong>In the temporarily absence of a specialised hospital pharmacist, the resolution rate of prescribing errors remains high when advice about prescribing errors is provided by a substitute hospital pharmacist.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143390431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of statin-induced muscle and liver adverse drug reactions in the Chinese population: a retrospective analysis of clinical trial data from 1992 to 2023.","authors":"Leo Tsui, Dan Wang, Chuyun Fan, Yule Huang, Zhiwen Zhang, Zhongjian Fang, Wei Xie","doi":"10.1136/ejhpharm-2024-004352","DOIUrl":"https://doi.org/10.1136/ejhpharm-2024-004352","url":null,"abstract":"<p><strong>Objectives: </strong>This study addressed the gaps in the disclosure of statin-associated adverse drug reactions (ADRs) in China's official database and the inadequacy of cases reported relative to the population size in public ADR databases.</p><p><strong>Methods: </strong>To address these limitations, we conducted a retrospective trial-based analysis using data from Chinese journals to comprehensively assess statin-associated ADRs from 1992 to 2023, focusing on liver (2895 studies, n = 163 810) and muscle (2888 studies, n = 161 714) related outcomes.</p><p><strong>Results: </strong>For large sample size clinical trial analysis (n≥100), our analysis encompassed data from 31 763 participants for muscle-related ADRs (incidence rate: 0.004-0.006, common effect model; 0.002-0.006, random effects model) and 31 281 participants for liver-related ADRs (incidence rate: 0.004-0.006, common effect model; 0.003-0.006, random effects model), covering various statins, including atorvastatin, simvastatin, rosuvastatin, fluvastatin, pitavastatin, pravastatin and lovastatin. Notably, muscle-related ADRs, particularly rhabdomyolysis, were most prevalent with fluvastatin, lovastatin and pravastatin, showing rates of 0.90%, 0.74% and 0.53%, respectively. Pitavastatin and atorvastatin were frequently associated with liver-related ADRs such as abnormal liver function and elevated enzymes, with rates of 5.36% and 1.819%, respectively.</p><p><strong>Conclusions: </strong>This study underscores significant variations in ADR incidence among different statins in the Chinese population, providing critical insights for healthcare professionals and policymakers to enhance patient safety and optimise clinical decisions regarding statin therapy.</p>","PeriodicalId":12050,"journal":{"name":"European journal of hospital pharmacy : science and practice","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}